Association of serum CTRP9 levels with cardiac autonomic neuropathy in patients with type 2 diabetes mellitus

Journal of Diabetes Investigation

卷:12

Yi Chen¹  Xiaobing Wang²  Yuehua Ma²  Xiaoyang Shi²  Yinghua Lv²  Junpeng Yang²  Huijuan Yuan²  Dongni Zhao³ 

[1] Clinical Research Service Center Henan Provincial People’s Hospital People’s Hospital of Zhengzhou University Zhengzhou Henan China;

[2] Department of Endocrinology Henan Provincial People’s Hospital People’s Hospital of Zhengzhou University Zhengzhou Henan China;

[3] Department of Finance Henan Provincial People’s Hospital People’s Hospital of Zhengzhou University Zhengzhou Henan China;

关键词: C1q TNF‐related protein 9;    Cardiac autonomic neuropathy;    Type 2 diabetes;   

DOI  :  10.1111/jdi.13495

来源: DOAJ

【 摘 要 】

Abstract Aims Cardiac autonomic neuropathy (CAN) is a serious complication of diabetes and is associated with adipokines. The C1q tumor necrosis factor‐related protein 9 (CTRP9) is a newly discovered adipokine. This study aimed to evaluate the association of serum CTRP9 levels with the prevalence and severity of CAN in patients with type 2 diabetes mellitus. Materials and Methods We enrolled 262 patients (aged ≥18 years) with type 2 diabetes mellitus into this study. Standard cardiovascular autonomic reflex tests (CARTs) were used to assess CAN and patients were divided into three groups accordingly: a non‐CAN group, an early CAN group, and a definite CAN group. Serum CTRP9 levels were measured by enzyme‐linked immunosorbent assay, and the tertiles were calculated. Results Serum CTRP9 levels decreased significantly in the early CAN and definite CAN groups (P < 0.05). The percentage of definite CAN was the highest at the minimum tertile of serum CTRP9 level (T1; P < 0.05). Additionally, serum CTRP9 levels were negatively correlated with age, DM duration, hemoglobin A1c (HbA1c), and fasting plasma glucose (FPG) while positively correlated with high‐density lipoprotein cholesterol (HDL; P < 0.05). The level of CTRP9 was also significantly associated with the four indexes of CARTs (P < 0.05). Furthermore, CTRP9 was a protective factor for definite CAN (P < 0.05). Compared with the maximum tertile (T3) of the serum CTRP9 levels, a decreased level of serum CTRP9 in T1 significantly increased the prevalence ratio of definite CAN in patients with type 2 diabetes mellitus (P < 0.05). Conclusion Serum CTRP9 levels were independently associated with definite CAN. CTRP9 represents a reliable biomarker for exploring CAN in patients with type 2 diabetes mellitus.

【 授权许可】

Unknown